Vertex to acquire Crinetics Pharmaceuticals in $10B deal

Vertex to acquire Crinetics Pharmaceuticals in $10B deal
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Spicy Projects #4: Vertex Protocol
VC’s Boundary-Breaking Marketing: How Vertex Capital’s Gamified Strategy in the TON Ecosystem is Expanding Investment Horizons
Vertex to acquire ecosio
2.8BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US92538J1060
CUSIP
92538J106
Sector
Technology
Industry
Software - Application
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
1.16
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.3
Wall Street Target Price
20.85
EPS Estimate Current Year
0.86
EPS Estimate Next Year
1.04
EPS Estimate Current Quarter
0.2217
EPS Estimate Next Quarter
0.2278
Most Recent Quarter
-
Revenue TTM
808,601,984
Gross Profit TTM
522,468,992
EBITDA
32,226,000
Profit Margin
-5.83%
Return On Assets TTM
1.32%
Return On Equity TTM
-21.19%
Revenue Per Share TTM
5.031
Qtly Revenue Growth YOY
11.00%
Diluted Eps TTM
-0.3
Qtly Earnings Growth YOY
-44.00%
Trailing PE
0.00
Forward PE
12
Price Sales TTM
3.4577
Price Book MRQ
15.5187
Enterprise Value Revenue
3
Enterprise Value EBITDA
30
302.81
0.64%88.83
0.03%126.10
-4.39%259.06
-3.80%198.07
-2.18%64.24
-2.18%199.68
-1.89%218.75
-1.46%182.20
-0.87%